BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 18423779)

  • 1. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ; Soon-Shiong P; Desai N
    Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin-bound paclitaxel in solid tumors: clinical development and future directions.
    Kundranda MN; Niu J
    Drug Des Devel Ther; 2015; 9():3767-77. PubMed ID: 26244011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies.
    Loong HH; Chan AC; Wong AC
    J Cancer; 2016; 7(3):268-75. PubMed ID: 26918039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective.
    Dranitsaris G; Yu B; King J; Kaura S; Zhang A
    Clinicoecon Outcomes Res; 2015; 7():249-56. PubMed ID: 25999749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles.
    Kianfar E
    J Nanobiotechnology; 2021 May; 19(1):159. PubMed ID: 34051806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas.
    Tian Z; Yao W
    Front Oncol; 2022; 12():815900. PubMed ID: 35223497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel.
    Huang JW; Kuo CH; Kuo HC; Shih JY; Tsai TW; Chang LC
    PLoS One; 2021; 16(3):e0248942. PubMed ID: 33740022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in Fatty Acid Oxidation between
    Huang JW; Kuo CH; Kuo HC; Shih JY; Tsai TW; Chang LC
    ACS Omega; 2021 Mar; 6(8):5138-5145. PubMed ID: 33681555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
    Kratz F
    J Control Release; 2008 Dec; 132(3):171-83. PubMed ID: 18582981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery.
    Fu Q; Sun J; Zhang W; Sui X; Yan Z; He Z
    Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):262-72. PubMed ID: 19538176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin-based nanoparticles as potential controlled release drug delivery systems.
    Elzoghby AO; Samy WM; Elgindy NA
    J Control Release; 2012 Jan; 157(2):168-82. PubMed ID: 21839127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F; Borgonovo K; Barni S
    Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. nab-Paclitaxel mechanisms of action and delivery.
    Yardley DA
    J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of albumin on drug delivery--new applications on the horizon.
    Elsadek B; Kratz F
    J Control Release; 2012 Jan; 157(1):4-28. PubMed ID: 21959118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
    Guarneri V; Dieci MV; Conte P
    Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.
    Miele E; Spinelli GP; Miele E; Tomao F; Tomao S
    Int J Nanomedicine; 2009; 4():99-105. PubMed ID: 19516888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling.
    Dave B; Granados-Principal S; Zhu R; Benz S; Rabizadeh S; Soon-Shiong P; Yu KD; Shao Z; Li X; Gilcrease M; Lai Z; Chen Y; Huang TH; Shen H; Liu X; Ferrari M; Zhan M; Wong ST; Kumaraswami M; Mittal V; Chen X; Gross SS; Chang JC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8838-43. PubMed ID: 24876273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivering nanomedicine to solid tumors.
    Jain RK; Stylianopoulos T
    Nat Rev Clin Oncol; 2010 Nov; 7(11):653-64. PubMed ID: 20838415
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.